ARECOR THERAPEUTICS PLC

Report Publication Announcement • Apr 27, 2022

National Storage Mechanism | Additional information

RNS Number : 4464J

Arecor Therapeutics PLC

27 April 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

Arecor to present on Investor Meet Company Platform

Cambridge, UK, 27 April 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Sarah Howell, Chief Executive Officer and Susan Lowther, Chief Financial Officer will be providing a live presentation relating to the Group's recently announced Year End Results for the year ended 31 December 2021 via the Investor Meet Company platform, on Thursday 5 May 2022 at 10:00am BST.

The presentation is open to all existing and potential shareholders and will be followed by a Q&A session. Questions can be submitted ahead of the event through the Investor Meet Company dashboard until 9am BST on Wednesday 4 May, or at any time during the live presentation.

To sign up to Investor Meet Company for free and to register for Arecor's presentation, please visit: https://www.investormeetcompany.com/arecor-therapeutics-plc/register-investor. Investors who already follow Arecor on the Investor Meet Company platform will automatically be invited to the event.

-ENDS-

For more information, please contact:

Arecor Therapeutics plc	www.arecor.com
Dr Sarah Howell, Chief Executive Officer	Tel: +44 (0) 1223 426060 Email: info@arecor.com
Susan Lowther, Chief Financial Officer	Tel: +44 (0) 1223 426060 Email: info@arecor.com
Mo Noonan, Communications	Tel: +44 (0) 7876 444977 Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking)	Tel: +44 (0) 20 7886 2500
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Gray	Tel: +44 (0) 20 3709 5700 Email: arecor@consilium-comms.com

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. 

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUNAKRUSUSUAR